A Review on the Clinical Utility of PSA in Cancer Prostate

被引:110
作者
Mohan Adhyam
Anish Kumar Gupta
机构
[1] Department of Genitourinary Surgery, St. John's Medical College, Bangalore
关键词
Prostate cancer; Prostate cancer diagnosis; Prostate cancer treatment; Prostate Specific Antigen (PSA);
D O I
10.1007/s13193-012-0142-6
中图分类号
学科分类号
摘要
Prostate cancer has come to share the oncological centrestage among male cancers. The availability of Serum Prostate Specific Antigen, PSA, as a marker has encouraged it's use to diagnose both cancer and cancer recurrence. Some clarity is required about its precise role in clinical practice. The available literature on Prostate Specific Antigen was reviewed; Articles were reviewed for content, applicability to the problem at hand, availability of data about sensitivity and specificity of values, refinements in measurements and finally for impact of screening programmes using these values on survival and quality of life. The data in the literature was critically re-evaluated and analysed to draw reasonable conclusions. Serum PSA measurements show variable reliability when it comes to diagnosis of Prostate cancer, given the dynamics of PSA physiology. Surrogate measures like PSA density, PSA velocity, free-to-complexed PSA ratio, percentage Pro-PSA, etc., have been used to improve the predictive utility of this assay for Prostate cancer. The ability of PSA to detect those cancers that will cost life, and thereby permit early curative treatment, is as yet unclear. It's most definitive role appears to be in diagnosing recurrences after adequate surgical treatment, and in evaluating response to treatment. © 2012 Indian Association of Surgical Oncology.
引用
收藏
页码:120 / 129
页数:9
相关论文
共 93 条
[1]  
Ries L.A.G., Melbert D., Krapcho M., Et al., SEER Cancer Statistics Review, 1975 2004, (2007)
[2]  
(2001)
[3]  
Lilja H., Christensson A., Dahlen U., Et al., Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin, Clin Chem, 37, (1991)
[4]  
Mikolajczyk S.D., Marks L.S., Partin A.W., Rittenhouse H.G., Free prostate-specific antigen in serum is becoming more complex, Urology, 59, (2002)
[5]  
Bjork T., Piironen T., Pettersson K., Et al., Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer, Urology, 48, (1996)
[6]  
Christensson A., Bjork T., Nilsson O., Et al., Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer, J Urol, 150, (1993)
[7]  
Partin A.W., Hanks G.E., Klein E.A., Et al., Prostate-specific antigen as a marker of disease activity in prostate cancer, Oncology (Williston Park), 16, (2002)
[8]  
Balk S.P., Ko Y.J., Bubley G.J., Biology of prostate-specific antigen, J Clin Oncol, 21, (2003)
[9]  
Crawford E.D., Prostate cancer awareness week: September 22 to 28, 1997, CA Cancer J Clin, 47, (1997)
[10]  
Oesterling J.E., Jacobsen S.J., Chute C.G., Et al., Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges, Jama, 270, (1993)